Kang Zhi Pharmaceutical Industry "Drug Safety" Door

At the beginning of the year of the rabbit, the gem began to get into a quagmire of drug safety.

stay

Yesterday, kaichi pharmaceutical was immediately suspended by the Shenzhen Stock Exchange, but it was resumed in the afternoon.

Although the company tried to clarify the theory of drug poisoning, its share price still suffered heavy losses, closing down more than 5%, hitting the limit.

According to the early announcement of the Shenzhen Stock Exchange yesterday morning, the public information about Kang Zhi pharmaceutical industry may have a greater impact on the company's stock trading price. After application, the company temporarily suspended its stock and waited until the company cleared the announcement by the designated media.

According to the twenty-first Century economic report, the paper investigated the adverse drug reactions in the country.

More than 20 cases were involved. Among them, some children died of severe liver damage due to one case of multiple organ dysfunction caused by the use of Ganzhi, a leading product of Kang Zhi medicine.

A researcher from a brokerage industry in Shenzhen pointed out that if the adverse reactions caused by nimesulide further aroused widespread concern in the society, the listed companies of nimesulide, such as Kang Zhi pharmaceutical, will face greater operational risks.

Hainan Kang Zhi pharmaceutical was listed on GEM in May last year.

As a production and sales company for children's medicine, Rui Zhi Qing (Nimesulide Granules) is its fist product. Its market share ranks first among the same products.

Kang Zhi pharmaceutical has not kept investors waiting too long for the safety of these products.

At noon yesterday, Kang Zhi pharmaceutical industry issued a clarification notice.

The bulletin stated that the twenty-first Century economic report entitled "Ni Mei Shug Leigh sweeps around the main business of the Kang Zhi pharmaceutical industry or encountered a crisis" is not true about the company's main business and its product, Nimesulide Granules.

The content of the report is quite inconsistent with the facts. The contents of serious liver damage and death cases mentioned in this article are not directly related to Ruzhi Qing.

However, although Kang Zhi pharmaceutical industry made clarification, but the afternoon resumption of the company's stock is not to force, directly with the limit price opened.

Although it rose, it still dropped 5.02%.

News link

CCTV warning nimesulide storage security risks

According to CCTV, in November 26, 2010, at the International Forum on child drug safety in Beijing attended by the leaders of the State Food and drug administration, children experts from the United States and Britain, as well as hundreds of pediatrician and professors from all over the country, unanimously reminded parents to use nimesulide cautiously in the choice of children's fever medication.

According to the data of China's ADR monitoring center, Ni Mei Shug Leigh has been listed in China for six years, and thousands of adverse events have occurred and even several deaths have occurred.

It is understood that in 2007, the European Commission for drug control issued a comprehensive ban on the use of Ni Mei Shug Leigh in children under 12 years of age, and in the instructions highlighted the special warning of serious liver damage risk.

In the United States, Ni Mei Shug Leigh's use of children has never been approved.